#oppenheimer
Latest news and interesting information about oppenheimer.
Equillium SVP & COO sells $267,209 in shares
Equillium COO Christine Zedelmayer sells $267,209 in shares. Analysts optimistic about EQ504 drug pipeline.
Stifel Reinstates Clean Harbors with Buy Rating
Stifel reinstated Clean Harbors with a Buy rating and $337 target. Learn about the company's market leadership, growth catalysts, and recent acquisitions.
Oppenheimer Starts Adlai Nortye at Outperform
Oppenheimer starts Adlai Nortye with Outperform rating and $32 target. Key pipeline assets AN4035 and AN8025 highlighted.
Oppenheimer Initiates Vulcan Materials at Perform
Oppenheimer initiates Vulcan Materials with a Perform rating, highlighting sunbelt market positions and strong financial health.
Oppenheimer Cuts Deere Price Target on Brazil Weakness
Oppenheimer cut Deere's price target to $680 from $715, citing Brazil agricultural weakness and tariff impacts, while maintaining an Outperform rating.
2026 S&P 500 and GDP growth forecasts
2026 S&P 500 targets and GDP growth forecasts from leading brokerages including Goldman Sachs, Morgan Stanley, and more.
GE Healthcare Director Kevin Lobo Buys $641,800 in Stock
GE Healthcare director Kevin Lobo buys $641,800 in stock. Detailed analysis on Bond.az.
Wolfe Research Reaffirms Ionis Stock Outperform Rating
Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.
Oppenheimer Raises EnerSys Target to $250
Oppenheimer raises EnerSys price target to $250, citing strong fiscal Q4 results and upbeat guidance. Learn about key growth drivers.
Ouster CRO sells $350,000 in stock
Ouster CRO Cyrille Jacquemet sold $350,000 worth of company stock. The stock returned 237% but Bond.az analysis shows it is overvalued.
Semtech Stock Hits Record High: $149.4
Semtech Corporation stock hits all-time high of $149.34. 1-year gain 268%, market cap $13.81B. Analyst upgrades and new product launch.
Oppenheimer Reaffirms Analog Devices Stock Rating
Oppenheimer reaffirms Outperform rating for Analog Devices (ADI) amid AI demand and strong quarterly results, with a $450 price target.
Republic Services CAO Sells $77,876 in Stock
Republic Services CAO Elyse Carlsen sold $77,876 in stock. After sale, she holds 552 shares. Company reported strong quarterly results.
Crescent Capital CFO Buys $11,120 in Stock
Crescent Capital BDC CFO Gerhard Lombard purchases $11,120 in common stock. The company offers a 13% dividend yield.
Crescent Capital director buys $958,485 in stock
Crescent Capital BDC director Steven F. Strandberg purchased $958,485 worth of common stock. Analyst ratings and financial updates included.
Marvell Technology stock hits all-time high at 192.21 USD
Marvell Technology stock hits all-time high at 192.21 USD, with 217% yearly gain and $167B market cap. Analyst targets raised.
William Blair Starts Insulet at Outperform
William Blair initiates Insulet at Outperform. Stock trades at 24x EPS, undervalued per Bond.az. Key concerns and catalysts detailed.
Piper Sandler Reiterates Overweight on Climb Bio
Piper Sandler reiterates Overweight on Climb Bio. IgAN opportunity and CLYM116 outlook.
Raymond James Backs Nutrien Stock on Potash
Raymond James backs Nutrien stock with Outperform rating and $90 target after Indian potash deal. 26% upside, strong financials.
Oppenheimer Reiterates Outperform on UroGen Pharma
Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.
Gates Buys $101.8M Republic Services Stock
William H. Gates III and Cascade Investment bought 486,000 Republic Services shares for $101.8 million. Read about the company's recent financial performance and analyst ratings.
Piper Sandler Lowers Figma Target on Margin
Piper Sandler cuts Figma price target to $30 from $35 due to margin pressure, despite strong revenue growth of 46% in Q1.
Piper Sandler Raises Biogen Target to $225
Piper Sandler raises Biogen price target to $225 from $214. Phase II trial of BIIB080 missed primary endpoint but showed slowing of clinical decline at lowest dose.
Forgent Power Solutions Target Raised to $60 by Oppenheimer
Oppenheimer raises Forgent Power Solutions price target to $60 on strong quarterly results. Stock up 24%.
Oppenheimer Downgrades Crescent BDC on Weak Returns
Oppenheimer downgrades Crescent BDC to Perform, cuts price target to $16. Stock at $11.99, weak Q1 results.
AAON director Gary Fields sells $2.6M in stock
AAON director Gary Fields sells 19,081 shares for $2.6M after option exercise. Stock up 84% YTD.
AAON CEO sells $1.08 million in stock
AAON CEO Matthew Tobolski sold $1.08 million in company stock at $135.37 per share. The stock surged 84% YTD. Recent earnings beat expectations.
Clean Harbors director buys $135,759 in stock
Clean Harbors director Karyn Polito buys $135,759 in stock. Read about the company's financial results and analyst estimates.
...